Experienced in Ulcerative Colitis

Corina A. Hartman

14 Kaplan Street, 
Petah Tiqwa, M, IL 
Experienced in Ulcerative Colitis
14 Kaplan Street, 
Petah Tiqwa, M, IL 
OverviewLocationsClinical Research

Overview

Corina Hartman practices in Petah Tiqwa, Israel. Ms. Hartman is rated as an Experienced expert by MediFind in the treatment of Ulcerative Colitis. Her top areas of expertise are Malabsorption, Celiac Disease, Viral Gastroenteritis, and Malnutrition.

Her clinical research consists of co-authoring 40 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles and participated in 2 clinical trials in the study of Ulcerative Colitis.

Gender
Female

Locations

14 Kaplan Street, Petah Tiqwa, M 49202, Israel

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
Enrollment Status: Completed
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Vedolizumab
Study Phase: Phase 3
Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases (IBD) Including Drug Levels: a Multi-center Prospective Cohort Study, From the Pediatric IBD Porto Group of European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)
Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases (IBD) Including Drug Levels: a Multi-center Prospective Cohort Study, From the Pediatric IBD Porto Group of European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)
Enrollment Status: Completed
Publish Date: October 25, 2022
Intervention Type: Drug
Study Drug: Vedolizumab
Study Phase: Not Applicable
View 1 Less Clinical Trial

40 Total Publications

The Variable Response to Teduglutide in Pediatric Short Bowel Syndrome: A Single Country Real-Life Experience.
The Variable Response to Teduglutide in Pediatric Short Bowel Syndrome: A Single Country Real-Life Experience.
Journal: Journal of pediatric gastroenterology and nutrition
Published: June 22, 2022

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Hartman's expertise for a condition
ConditionClose
        View All 12 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile